Vaccination Against Tuberculosis With Whole-Cell Mycobacterial Vaccines.

Scriba TJ; Kaufmann SH; Henri Lambert P; Sanicas M; Martin C; Neyrolles O

doi:10.1093/infdis/jiw228

Back

Journal article

Vaccination Against Tuberculosis With Whole-Cell Mycobacterial Vaccines.

Scriba TJ Department of Pathology, South African Tuberculosis Vaccine Initiative Institute of Infectious Disease and Molecular Medicine Division of Immunology, University of Cape Town, South Africa.
Kaufmann SH Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany.
Henri Lambert P Center of Vaccinology, University Medical Center, University of Geneva, Switzerland.
Sanicas M Bill and Melinda Gates Foundation, Seattle, Washington.
Martin C Department of Microbiology, Faculty of Medicine, University of Zaragoza ISS Aragón Zaragoza CIBER Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.
Neyrolles O CNRS, IPBS (Institut de Pharmacologie et de Biologie Structurale) Université de Toulouse, UPS, IPBS, France.

2016-06-02

Published in:

The Journal of infectious diseases. - 2016

English Live attenuated and killed whole-cell vaccines (WCVs) offer promising vaccination strategies against tuberculosis. A number of WCV candidates, based on recombinant bacillus Calmette-Guerin (BCG), attenuated Mycobacterium tuberculosis, or related mycobacterial species are in various stages of preclinical or clinical development. In this review, we discuss the vaccine candidates and key factors shaping the development pathway for live and killed WCVs and provide an update on progress.

Language